Botox migraine treatment to be assessed by NICE

Treatment of migraine with botulinum toxin type A is to be assessed by NICE, details of the institute's latest work programme reveal.

A technology appraisal will assess ‘the clinical and cost effectiveness of botulinum toxin type A within its licensed indication for the prophylaxis of headaches associated with chronic migraine’.

After botulinum toxin was licensed for treating chronic migraine, RCGP headache champion Dr David Kernick warned in GP that practical and funding issues would initially limit availability of the treatment. However, if botulinum toxin type A is accepted for the treatment of migraine by NICE, NHS services will have a legal duty to provide access to it.

Other treatments to be assessed by NICE include lenalidomide for multiple myeloma and myelodysplastic syndromes and erlotinib for lung cancer. Treatments are referred to NICE for appraisal by ministers. The topics selected by ministers have undergone a consultation process on the remit and scope of the appraisals NICE should undertake.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus